Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
TraceSafe (TSF.CN), an emerging global technology firm delivering hardware and software solutions to improve workplace efficiency, ensure health and safety measures, and streamline quarantine management, announced many updates between climate actions, new solutions, to partnering. For the last couple of months, the company turned from Covid solutions to carbon projects.
TraceSafe is a Canadian-based company with offices in Toronto, Singapore, India, and the United States. The company was first primarily focused on providing a full suite of real-time location management services and contact tracing solutions enabled through advanced low-power Bluetooth beacons and enterprise cloud management. Its answer, TraceSafe’s patented contact tracing bracelet, was handy during the pandemic and was deployed in mission-critical quarantine applications worldwide in partnership with leading governments. This solution brought solid revenues for the year 2021, but since the pandemic got better, revenues aligned to this sector subsequently decreased. The company decided to take an ecological turn and focus on carbon solutions. This path was recently highlighted by the company’s move to join the United Nations Accredited Climate Chain Coalition. This coalition is an open global initiative to support collaboration among members and stakeholders to advance blockchain (distributed ledger technology) and related digital solutions (e.g., IoT, big data) to help mobilize climate finance and enhance MRV (measurement, reporting, and verification) to scale climate actions for mitigation and adaptation. On September 21, the company partnered with Green Marine, a voluntary environmental certification program for the North American marine industry.
“We are honored and excited to become a partner member of Green Marine, a leader in environmental stewardship for the marine industry. Their participants represent the most important names in the marine and shipping industry in North America, and we can’t wait to help them reach their climate goals with ShiftCarbon.”
Wayne Lloyd, TraceSafe CEO.
Wayne Lloyd leads the company. Mr. Lloyed is a technology entrepreneur active in tech M&A. He serves as an investor, trader, board member, and advisor to several technologies and fintech startups.
Many countries aim to reduce their carbon emissions in the future, creating a vast market opportunity for climate companies. 49 countries and 93 Fortune 500 companies have committed to net zero targets, expanding market opportunities in climate tech.
In 2021, US VC investment in climate tech increased by 80% compared to 2020, reaching $56B, with energy and power experiencing the fastest growth.
TraceSafe took the initiative to launch ShiftCarbon, a comprehensive carbon management platform. It will consolidate critical climate data for Small & Midsize Businesses and help them reduce their carbon footprint using high-quality offsets. The platform will enable:
With the platform, the company announced the launch of ThermoSense. It is a sensor-based approach to a sustainable supply chain, followed by the acquisition of Offsety- a carbon offset marketplace for managed decarbonization and, most recently, the launch of its events emissions calculator that will help global sporting events reach net zero faster.
On August 26, the company released its financials for the period ending June 30. For the company’s balance sheet, it announced $67k in cash and $2.2M in investment for a total of $3.2M in total assets. Regarding liabilities, the company announced $5M for this period. TraceSafe generated $779k in revenue for Q2 and reported a $1.1M net loss after tax. This number is driven by personnel expenses which accounted for $777k, professional fees ($439k), and research & development ($337k). If these expenses are subsequent, they decreased by 50% ($5.8M in 2021 vs. $2.9M in 2022) for the last 6 months compared to the same period of the previous year. The company’s gross margin significantly increased to $779,177 compared to the 2021 period of $389,139. This was due to a shift in demand from lower margin to higher margin Service Income product line. The company announced on August 17 that it had secured financing to power new carbon products and growth. TraceSafe obtained $500k in exchange for 3.33M units at a price of $0.15. These units are entitled to a warrant at an exercise price of $0.3. With this financing, the company aims to take a new direction toward decarbonization following the launch of its comprehensive carbon management solution named ShiftCarbon.
“We have made significant progress on our growth plans that include the new decarbonization and net-zero focus in the last six months. With this financing, we will strengthen customer outreach for our carbon platform and geographic expansion of our IoT solutions in the Middle East.”
Wayne Lloyd, TraceSafe CEO.
TraceSafe (TSF.CN) decided to take a green turn and makes the correct choices. The company augments its presence in the climate industry with the launch of its platform ShiftCarbon, its recent participation in the United Nations Accredited Climate Chain Coalition, and its recent partnering with Green Marine to strengthen its decarbonization offerings for the marine industry. The revenues have remained steady since the beginning of the year, but the new market opportunity chosen by the company will open new doors, resulting in new incomes for TraceSafe.
©2024 10xAlerts